Novel eicosanoid analgesics
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Jun 24, 2004
app pub date -
Feb 13, 2003
filing date -
Jun 20, 2001
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
Analogs of andandamide and arvanil have been found to act preferential at CB.sub.1 and AR.sub.1 receptors, and at receptors other than CB.sub.1 and AR.sub.1. The analogs provide analgesic effects in vivo, and are useful in pain management. In addition, the analogs may be used as anti-proliferative/anti-tumor agents, vasodilators, and in other applications. Several of the anandamide and arvanil analogs are more potent than anandamide and arvanil.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully